nach oben

Erschienen in:

28.09.2023 | Peritoneal Surface Malignancy

Results of the First Phase I PIPAC Trial in the United States: Braving the Storm

verfasst von: Beatrice J. Sun, MD, Byrne Lee, MD, FACS, FSSO

Erschienen in: Annals of Surgical Oncology | Ausgabe 13/2023

Einloggen, um Zugang zu erhalten

Auszug

The peritoneum is a common site of metastasis in colorectal and appendiceal cancers and is associated with poor prognosis. Treatment of peritoneal metastases (PM) is challenging and while cytoreductive surgery (CRS) with or without hyperthermic intraperitoneal chemotherapy (HIPEC) is an option for select patients with PM, those with unresectable high burden of peritoneal disease are limited to systemic options. Unfortunately, chemotherapy has demonstrated poor efficacy and lower overall survival (OS) in the treatment of PM when compared with metastases of non-peritoneal sites, and thus additional treatment options are desperately needed.¹ …

Franko J, Shi Q, Meyers JP, et al. Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database. Lancet Oncol. 2016;17(12):1709–19. https://doi.org/10.1016/S1470-2045(16)30500-9.CrossRefPubMed

Solass W, Herbette A, Schwarz T, et al. Therapeutic approach of human peritoneal carcinomatosis with Dbait in combination with capnoperitoneum: proof of concept. Surg Endosc. 2012;26(3):847–52. https://doi.org/10.1007/s00464-011-1964-y.CrossRefPubMed

Solass W, Kerb R, Mürdter T, et al. Intraperitoneal chemotherapy of peritoneal carcinomatosis using pressurized aerosol as an alternative to liquid solution: first evidence for efficacy. Ann Surg Oncol. 2014;21(2):553–9. https://doi.org/10.1245/s10434-013-3213-1.CrossRefPubMed

Raoof M, Whelan RL, Sullivan KM, et al. Safety and efficacy of oxaliplatin pressurized intraperitoneal aerosolized chemotherapy (PIPAC) in colorectal and appendiceal cancer with peritoneal metastases: results of a multicenter phase I trial in the USA. Ann Surg Oncol. 2023. https://doi.org/10.1245/s10434-023-13941-2.CrossRefPubMedPubMedCentral

Rovers KP, Wassenaar ECE, Lurvink RJ, et al. Pressurized intraperitoneal aerosol chemotherapy (oxaliplatin) for unresectable colorectal peritoneal metastases: a multicenter, single-arm, phase II trial (CRC-PIPAC). Ann Surg Oncol. 2021;28(9):5311–26. https://doi.org/10.1245/s10434-020-09558-4.CrossRefPubMed

Kim G, Tan HL, Sundar R, et al. PIPAC-OX: a phase I study of oxaliplatin-based pressurized intraperitoneal aerosol chemotherapy in patients with peritoneal metastases. Clin Cancer Res. 2021;27(7):1875–81. https://doi.org/10.1158/1078-0432.CCR-20-2152.CrossRefPubMed

Taibi A, Sgarbura O, Hübner M, et al. Feasibility and safety of oxaliplatin-based pressurized intraperitoneal aerosol chemotherapy with or without intraoperative intravenous 5-fluorouracil and leucovorin for colorectal peritoneal metastases: a multicenter comparative cohort study. Ann Surg Oncol. 2022;29(8):5243–51. https://doi.org/10.1245/s10434-022-11577-2.CrossRefPubMed

Sgarbura O, Hübner M, Alyami M, et al. Oxaliplatin use in pressurized intraperitoneal aerosol chemotherapy (PIPAC) is safe and effective: a multicenter study. Eur J Surg Oncol. 2019;45(12):2386–91. https://doi.org/10.1016/j.ejso.2019.05.007.CrossRefPubMed

Marin D, Catalano C, Baski M, et al. 64-Section multi-detector row CT in the preoperative diagnosis of peritoneal carcinomatosis: correlation with histopathological findings. Abdom Imaging. 2010;35(6):694–700. https://doi.org/10.1007/s00261-008-9464-9.CrossRefPubMed

10.

Dromain C, Leboulleux S, Auperin A, et al. Staging of peritoneal carcinomatosis: enhanced CT vs. PET/CT. Abdom Imaging. 2008;33(1):87–93. https://doi.org/10.1007/s00261-007-9211-7.CrossRefPubMed

11.

Goéré D, Glehen O, Quenet F, et al. Second-look surgery plus hyperthermic intraperitoneal chemotherapy versus surveillance in patients at high risk of developing colorectal peritoneal metastases (PROPHYLOCHIP-PRODIGE 15): a randomised, phase 3 study. Lancet Oncol. 2020;21(9):1147–54. https://doi.org/10.1016/S1470-2045(20)30322-3.CrossRefPubMed

12.

Graversen M, Detlefsen S, Ainsworth AP, et al. Treatment of peritoneal metastasis with pressurized intraperitoneal aerosol chemotherapy: results from the prospective PIPAC-OPC2 study. Ann Surg Oncol. 2023;30(5):2634–44. https://doi.org/10.1245/s10434-022-13010-0.CrossRefPubMed

13.

Ploug M, Graversen M, Pfeiffer P, Mortensen MB. Bidirectional treatment of peritoneal metastasis with pressurized intraperitoneal aerosol chemotherapy (PIPAC) and systemic chemotherapy: a systematic review. BMC Cancer. 2020;20:105. https://doi.org/10.1186/s12885-020-6572-6.CrossRefPubMedPubMedCentral

14.

Hübner M, Alyami M, Villeneuve L, et al. Consensus guidelines for pressurized intraperitoneal aerosol chemotherapy: technical aspects and treatment protocols. Eur J Surg Oncol. 2022;48(4):789–94. https://doi.org/10.1016/j.ejso.2021.10.028.CrossRefPubMed

15.

Nowacki M, Alyami M, Villeneuve L, et al. Multicenter comprehensive methodological and technical analysis of 832 pressurized intraperitoneal aerosol chemotherapy (PIPAC) interventions performed in 349 patients for peritoneal carcinomatosis treatment: an international survey study. Eur J Surg Oncol. 2018;44(7):991–6. https://doi.org/10.1016/j.ejso.2018.02.014.CrossRefPubMed

16.

Odendahl K, Solass W, Demtröder C, et al. Quality of life of patients with end-stage peritoneal metastasis treated with Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC). Eur J Surg Oncol. 2015;41(10):1379–85. https://doi.org/10.1016/j.ejso.2015.06.001.CrossRefPubMed

17.

Graversen M, Detlefsen S, Bjerregaard JK, Fristrup CW, Pfeiffer P, Mortensen MB. Prospective, single-center implementation and response evaluation of pressurized intraperitoneal aerosol chemotherapy (PIPAC) for peritoneal metastasis. Ther Adv Med Oncol. 2018;10:1758835918777036. https://doi.org/10.1177/1758835918777036.CrossRefPubMedPubMedCentral

Titel: Results of the First Phase I PIPAC Trial in the United States: Braving the Storm
verfasst von: Beatrice J. Sun, MD
Byrne Lee, MD, FACS, FSSO
Publikationsdatum: 28.09.2023
Verlag: Springer International Publishing
Erschienen in: Annals of Surgical Oncology / Ausgabe 13/2023
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI: https://doi.org/10.1245/s10434-023-14353-y

Major Intraoperative Complications During Minimally Invasive Esophagectomy

Open Access
Thoracic Oncology

Perioperative Chemotherapy is Associated with Superior Overall Survival in Patients with Synchronous Colorectal Liver Metastases

Hepatobiliary Tumors

Multidisciplinary Care: How to Win Friends and Influence Your Colleagues to Provide Quality Goals-of-Care Discussions

Global Health Services Research

Effects of TRPV2 on the Expression of PD-L1 and Its Binding Ability to PD-1 in Gastric Cancer

Translational Research

ASO Visual Abstract: Prognostic Factors and Clinical Outcomes in Extraskeletal Ewing Sarcoma—A Cohort Study

ASO Visual Abstract

ASO Visual Abstract: A Novel Injection Protocol Using Voluven®-Assisted Indocyanine Green with Improved Near-Infrared Fluorescence Guidance in Breast Cancer Sentinel Lymph Node Mapping: A Translational Study

ASO Visual Abstract

Neu im Fachgebiet Chirurgie

Lohnt sich die Karotis-Revaskularisation?

25.04.2025
Karotisstenose
Nachrichten

Die medikamentöse Therapie für Menschen mit Karotisstenosen hat sich in den vergangenen Dekaden verbessert. Braucht es also noch einen invasiven Eingriff zur Revaskularisation der Halsschlagader bei geringem bis moderatem Risiko für einen ipsilateralen Schlaganfall?

Höhere Dosis von Dexamethason senkt Überlebenschancen

25.04.2025
Zerebrale Metastasen
Nachrichten

Personen mit Hirnmetastasen, die perioperativ höhere kumulative Dosen von Dexamethason erhalten, haben eine schlechtere Prognose. Um die Ergebnisse zu verbessern, bedarf es strengerer Dosierungsschemata.

Appendektomie erhält Remission bei Colitis ulcerosa

24.04.2025
Colitis ulcerosa
Nachrichten

Wird der Wurmfortsatz bei Personen mit Colitis ulcerosa entfernt, ist die Rückfallrate um ein Drittel geringer als unter konservativer Behandlung. Auch die Lebensqualität verbessert sich und der Bedarf an Medikamenten nimmt ab.

Op.-Entscheidung bei Divertikulitis: Lebensqualität zählt!

22.04.2025
Divertikulitis
Nachrichten

Soll man Menschen, die schon mehrfach schmerzhafte Divertikulitisepisoden durchgemacht haben, eine Op. anbieten? Ein Team aus Helsinki rät, dies von der Lebensqualität abhängig zu machen.

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Results of the First Phase I PIPAC Trial in the United States: Braving the Storm

Auszug

Weitere Artikel der Ausgabe 13/2023

Major Intraoperative Complications During Minimally Invasive Esophagectomy

Perioperative Chemotherapy is Associated with Superior Overall Survival in Patients with Synchronous Colorectal Liver Metastases

Multidisciplinary Care: How to Win Friends and Influence Your Colleagues to Provide Quality Goals-of-Care Discussions

Effects of TRPV2 on the Expression of PD-L1 and Its Binding Ability to PD-1 in Gastric Cancer

ASO Visual Abstract: Prognostic Factors and Clinical Outcomes in Extraskeletal Ewing Sarcoma—A Cohort Study

ASO Visual Abstract: A Novel Injection Protocol Using Voluven®-Assisted Indocyanine Green with Improved Near-Infrared Fluorescence Guidance in Breast Cancer Sentinel Lymph Node Mapping: A Translational Study

Neu im Fachgebiet Chirurgie

Lohnt sich die Karotis-Revaskularisation?

Höhere Dosis von Dexamethason senkt Überlebenschancen

Appendektomie erhält Remission bei Colitis ulcerosa

Op.-Entscheidung bei Divertikulitis: Lebensqualität zählt!

Update Chirurgie

Springer Medizin

Auszug

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten